PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players

News provided by

Feb 06, 2014, 05:55 ET

NEW YORK, Feb. 6, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players
http://www.reportlinker.com/p02008765/PharmaPoint-Microvascular-Complications-of-Diabetes---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players

Summary

GlobalData has released its pharma report, "PharmaPoint: Microvascular Complications of Diabetes - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Microvascular Complications of Diabetes Market. The report identifies and analyses the key companies shaping and driving the global Microvascular Complications of Diabetes market. The report provides insight into the competitive Microvascular Complications of Diabetes landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

- Investigation of current and future market competition for Microvascular Complications of Diabetes
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the Microvascular Complications of Diabetes sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving the Microvascular Complications of Diabetes Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What's the next big thing in the global Microvascular Complications of Diabetes market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Market Outlook 13
3.1 Global Markets 13
3.1.1 Forecast 13
3.1.2 Drivers and Barriers – Global Issues 17
4 Current and Future Players 20
4.1 Overview 20
4.2 Trends in Corporate Strategy 22
4.3 Company Profiles 25

4.3.1 Roche 25
4.3.2 Novartis 27
4.3.3 Regeneron 29
4.3.4 Bayer 31
4.3.5 Eli Lilly 32
4.3.6 Pfizer 35
4.3.7 AbbVie 37
5 Appendix 40
5.1 Bibliography 40
5.2 Abbreviations 42
5.3 Methodology 44
5.4 Forecasting Methodology 44
5.4.1 Diagnosed Patients 44
5.4.2 Percent Drug-Treated Patients 45
5.4.3 General Pricing Assumptions 45
5.5 Physicians and Specialists Included in this Study 46
5.6 About the Authors 48
5.6.1 Analyst II – CVMD 48
5.6.2 Therapy Director – CVMD and Infectious Disease 48
5.6.3 Global Head of Healthcare 49
5.7 About GlobalData 50
5.8 Disclaimer 50

List of Tables

Table 1: Global Sales Forecasts ($) for MCD, 2012–2022 15
Table 2: MCD Market – Drivers and Barriers, 2013 17
Table 3: Key Companies in the MCD Market, 2013 21
Table 4: Roche/Genentech's MCD Portfolio Assessment, 2013 26
Table 5: Roche/Genentech SWOT Analysis, 2013 26
Table 6: Novartis' MCD Portfolio Assessment, 2013 28
Table 7: Novartis SWOT Analysis, 2013 28
Table 8: Regeneron's MCD Portfolio Assessment, 2013 30
Table 9: Regeneron SWOT Analysis, 2013 30
Table 10: Bayer's MCD Portfolio Assessment, 2013 31
Table 11: Bayer SWOT Analysis, 2013 32
Table 12: Eli Lilly's MCD Portfolio Assessment, 2013 34
Table 13: Eli Lilly SWOT Analysis, 2013 34
Table 14: Pfizer's MCD Portfolio Assessment, 2013 36
Table 15: Pfizer SWOT Analysis, 2013 37
Table 16: AbbVie's MCD Portfolio Assessment, 2013 38
Table 17: AbbVie SWOT Analysis, 2013 39
Table 18: Number of High-Prescribing Physicians Surveyed 47